Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CertaraCERT +0.06%65 Days Sales Outstanding is 80.36 as of Jun. 2026, which is 4% above its 10-year median of 77.36. GuruFocus rates CERT with a GF Score™ of 65/100 and a GF Value™ of $12.37 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 657 Healthcare Providers & Services companies, Certara ranks worse than 74.73% on this metric.
Certara's average Accounts Receivable for the
three
months ended in Jun. 2026 was $82.1 Mil. Certara's Revenue for the
three
months ended in Jun. 2026 was $93.3 Mil.
Hence, Certara's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 80.36.
The historical rank and industry rank for Certara's Days Sales Outstanding or its related term are showing as below:
CERT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.97 Med: 77.36 Max: 103.65
Current: 74.88
During the past 8 years, Certara's highest Days Sales Outstanding was 103.65. The lowest was 67.97. And the median was 77.36.
CERT's Days Sales Outstanding is ranked worse than 74.73% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 45.88
vs CERT: 74.88
Certara's Days Sales Outstanding
increased
from Jun. 2025 (79.62) to Jun. 2026 (80.36).
Certara (NAS:CERT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Certara Days Sales Outstanding Related Terms
Certara Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Certara's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERT vs SDGR, OMDA, GDRX: Days Sales Outstanding Comparison
For the Health Information Services subindustry, Certara's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Certara's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara (CERT) has a Days Sales Outstanding of 80.36 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Certara and its competitors. This is near median its historical median of 77.36. Over the past decade, Certara's Days Sales Outstanding has ranged from 67.97 to 103.65. According to the industry distribution chart, Certara ranks #491 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 74.7%.
Is Certara's Days Sales Outstanding too high?
Certara's current Days Sales Outstanding of 80.36 is near median its 10-year median of 77.36. Over the past 10 years, this metric has ranged from a low of 67.97 to a high of 103.65. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.88. Certara's value of 80.36 is 75.2% above this industry median. Based on the distribution chart, Certara ranks #491 out of 657 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Certara has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Certara's Days Sales Outstanding compare to SDGR and OMDA?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #491 out of 657 companies for Days Sales Outstanding. This places Certara in the lower half of its industry. The industry median Days Sales Outstanding is 45.88. Certara's value of 80.36 is 75.2% above this benchmark. Historically, Certara's own Days Sales Outstanding has ranged from 67.97 to 103.65 over the past decade. While the company's 10-year median is 77.36 vs. the industry median of 45.88, Certara has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.88, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Certara's current Days Sales Outstanding of 80.36 is 75.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Certara and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current Days Sales Outstanding is 80.36, which is near median its own 10-year median of 77.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.37, compared to a current price of $8.01 — trading 35.2% below its estimated fair value. The current Days Sales Outstanding is 80.36, which is near median its 10-year median of 77.36 and 75.2% above the Healthcare Providers & Services industry median of 45.88. Certara's overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Certara (CERT), the current Days Sales Outstanding is 80.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $8.01 is trading 35.2% below its estimated GF Value™ of $12.37.
GuruFocus considers Certara to be Significantly Undervalued.
Key valuation signals for CERT:
Days Sales Outstanding: 80.36 (near median its 10-year median of 77.36)
GF Value™: $12.37 vs. price of $8.01 (35.2% below fair value)
Industry Position: 75.2% above the Healthcare Providers & Services median (#491 of 657)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
65GF Score
Get the complete analysis for CERT
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
